AVERT System receives FDA clearance for controlled infusion of radiopaque comparison media in angiographic procedures Osprey Medical Inc sildenafil citrate . today announced that it has received U.S. The AVERT Program can be a proprietary technology made to reduce the amount of dye injected and subjected to sufferers going through angiogram or diagnostic center methods. In a pilot human being clinical research, the AVERT System was shown to reduce the amount of dye by up to 40 percent without compromising picture quality. There are 4 approximately. 4 million angiogram and STEMI heart procedures performed annually in Western European countries and the United States. AVERT had not been yet part of our plans whenever we undertook our IPO in May 2012. Developing the Avert System and obtaining FDA clearance in such a short period of period is definitely testament to the features of our team at Osprey and possibly opens up further fascinating opportunities for the business.
today announced that preclinical data on tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and the business’s monoclonal antibody pipeline will end up being presented during poster periods at the American Association for Cancer tumor Study 102nd Annual Meeting 2011 being kept April 2-6, 2011 in Orlando, Fla. ‘We anticipate posting these preclinical data on our business lead product applicant tivozanib and our deep pipeline of monoclonal antibodies with our peers in the oncology analysis community,’ mentioned William Slichenmyer, M.D., Sc.M., chief medical officer at AVEO.’.. AVEO to provide tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting AVEO Pharmaceuticals, Inc.